{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:26:44Z","timestamp":1790526404246,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Mantle cell lymphoma (MCL) accounts for 5%\u201310% of all lymphomas. The disease\u2019s genetic hallmark is the t(11; 14)(q13; q32) translocation. In younger patients, the first-line treatment is chemoimmunotherapy followed by autologous stem cell transplantation. Upon disease progression, novel and targeted agents such as the BTK inhibitor ibrutinib, the BCL-2 inhibitor venetoclax, or the combination of both are increasingly used, but even after allogeneic stem cell transplantation or CAR T-cell therapy, MCL remains incurable for most patients. Chronic antigenic stimulation of the B-cell receptor (BCR) is thought to be essential for the pathogenesis of many B-cell lymphomas. LRPAP1 has been identified as the autoantigenic BCR target in about 1\/3 of all MCLs. Thus, LRPAP1 could be used to target MCL cells, however, there is currently no optimal therapeutic format to integrate LRPAP1. We have therefore integrated LRPAP1 into a concept termed BAR, for B-cell receptor antigens for reverse targeting. A bispecific BAR body was synthesized consisting of the lymphoma-BCR binding epitope of LRPAP1 and a single chain fragment targeting CD3 or CD16 to recruit\/engage T or NK cells. In addition, a BAR body consisting of an IgG1 antibody and the lymphoma-BCR binding epitope of LRPAP1 replacing the variable regions was synthesized. Both BAR bodies mediated highly specific cytotoxic effects against MCL cells in a dose-dependent manner at 1\u201320 \u00b5g\/mL. In conclusion, LRPAP1 can substitute variable antibody regions in different formats to function in a new therapeutic approach to treat MCL.<\/jats:p>","DOI":"10.1097\/hs9.0000000000000620","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T18:14:17Z","timestamp":1626200057000},"page":"e620","source":"Crossref","is-referenced-by-count":6,"title":["The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells"],"prefix":"10.1002","volume":"5","author":[{"given":"Moritz","family":"Bewarder","sequence":"first","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kiefer","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Will","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Olesch","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Moelle","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Christofyllakis","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Kaddu-Mulindwa","sequence":"additional","affiliation":[{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg Thomas","family":"Bittenbring","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Fadle","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Regitz","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kaschek","sequence":"additional","affiliation":[{"name":"Biophysics, CIPMM, Saarland University, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hoth","sequence":"additional","affiliation":[{"name":"Biophysics, CIPMM, Saarland University, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Neumann","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Dieter","family":"Preuss","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Thurner","sequence":"additional","affiliation":[{"name":"Jos\u00e9 Carreras Center for Immuno- and Gene Therapy, Saarland University Medical Center, Homburg, Germany"},{"name":"Internal Medicine I, Saarland University Medical Center, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8]]},"reference":[{"key":"R1-20231201","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R2-20231201","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network.","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"R3-20231201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"R4-20231201","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma.","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20231201","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"R6-20231201","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma.","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"R7-20231201","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma.","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20231201","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R9-20231201","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-20231201","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial.","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"key":"R11-20231201","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies.","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"R12-20231201","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.","volume":"112","author":"Young","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20231201","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1172\/JCI82091","article-title":"Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor.","volume":"125","author":"Preuss","year":"2015","journal-title":"J Clin Invest"},{"key":"R14-20231201","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.24427","article-title":"A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS.","volume":"125","author":"Preuss","year":"2009","journal-title":"Int J Cancer"},{"key":"R15-20231201","first-page":"xxx","article-title":"Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell-type diffuse large B-cell lymphoma.","volume":"105","author":"Thurner","year":"2020","journal-title":"Haematologica"},{"key":"R16-20231201","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2018-03-836932","article-title":"Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.","volume":"132","author":"Thurner","year":"2018","journal-title":"Blood"},{"key":"R17-20231201","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41375-018-0182-1","article-title":"LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.","volume":"33","author":"Thurner","year":"2019","journal-title":"Leukemia"},{"key":"R18-20231201","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/geno.1994.1348","article-title":"Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1).","volume":"22","author":"Korenberg","year":"1994","journal-title":"Genomics"},{"key":"R19-20231201","doi-asserted-by":"crossref","first-page":"21232","DOI":"10.1016\/S0021-9258(18)54845-6","article-title":"39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein\/alpha 2-macroglobulin receptor.","volume":"266","author":"Herz","year":"1991","journal-title":"J Biol Chem"},{"key":"R20-20231201","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"key":"R21-20231201","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.","volume":"32","author":"Levy","year":"2014","journal-title":"J Clin Oncol"},{"key":"R22-20231201","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1084\/jem.144.4.960","article-title":"Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes.","volume":"144","author":"Hough","year":"1976","journal-title":"J Exp Med"},{"key":"R23-20231201","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/bjc.1980.271","article-title":"Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces.","volume":"42","author":"Hamblin","year":"1980","journal-title":"Br J Cancer"},{"key":"R24-20231201","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","article-title":"A clinical trial of anti-idiotype therapy for B cell malignancy.","volume":"65","author":"Meeker","year":"1985","journal-title":"Blood"},{"key":"R25-20231201","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"key":"R26-20231201","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1073\/pnas.1603335113","article-title":"Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies.","volume":"113","author":"Torchia","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-20231201","doi-asserted-by":"crossref","first-page":"580364","DOI":"10.3389\/fonc.2020.580364","article-title":"Integration of the B-cell receptor antigen Neurabin-I\/SAMD14 into an antibody format as new therapeutic approach for the treatment of primary CNS lymphoma.","volume":"10","author":"Bewarder","year":"2020","journal-title":"Front Oncol"},{"key":"R28-20231201","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1074\/jbc.274.26.18218","article-title":"A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.","volume":"274","author":"de Haard","year":"1999","journal-title":"J Biol Chem"},{"key":"R29-20231201","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1093\/nar\/19.15.4133","article-title":"Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.","volume":"19","author":"Hoogenboom","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"R30-20231201","doi-asserted-by":"crossref","first-page":"e109199","DOI":"10.1371\/journal.pone.0109199","article-title":"Towards the generation of B-cell receptor retrogenic mice.","volume":"9","author":"Freitag","year":"2014","journal-title":"PLoS One"},{"key":"R31-20231201","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity.","volume":"93","author":"NISONOFF","year":"1961","journal-title":"Arch Biochem Biophys"},{"key":"R32-20231201","first-page":"12","article-title":"Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.","volume":"12","author":"Riethm\u00fcller","year":"2012","journal-title":"Cancer Immun"},{"key":"R33-20231201","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical pharmacology and translational aspects of bispecific antibodies.","volume":"10","author":"Trivedi","year":"2017","journal-title":"Clin Transl Sci"},{"key":"R34-20231201","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia.","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"R35-20231201","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"R36-20231201","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"R37-20231201","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE(\u00ae)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications.","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R38-20231201","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jps.23783","article-title":"Pharmacokinetics of Peptide-Fc fusion proteins.","volume":"103","author":"Wu","year":"2014","journal-title":"J Pharm Sci"},{"key":"R39-20231201","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"R40-20231201","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R41-20231201","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies.","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:14:11Z","timestamp":1702923251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000620","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]}}}